Y Intercept Hong Kong Ltd Decreases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Y Intercept Hong Kong Ltd lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 26.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,409 shares of the company’s stock after selling 26,750 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Moderna were worth $3,094,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Intrinsic Value Partners LLC lifted its position in shares of Moderna by 91.1% in the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after purchasing an additional 24,505 shares during the period. Banco Santander S.A. bought a new position in Moderna in the third quarter worth about $3,550,000. John G Ullman & Associates Inc. raised its stake in Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after buying an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares during the period. Finally, abrdn plc boosted its position in Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after acquiring an additional 69,360 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on MRNA. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Leerink Partners lowered their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Wolfe Research initiated coverage on shares of Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Finally, JPMorgan Chase & Co. set a $45.00 target price on shares of Moderna in a research note on Friday, February 14th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $60.63.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 over the last three months. Insiders own 15.20% of the company’s stock.

Moderna Stock Performance

MRNA opened at $33.90 on Tuesday. The company’s 50-day simple moving average is $37.89 and its two-hundred day simple moving average is $52.10. The stock has a market capitalization of $13.05 billion, a P/E ratio of -3.65 and a beta of 1.59. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.